Suppr超能文献

理解肾细胞癌肾切除术后仅淋巴结复发时挽救性淋巴结清扫的作用。

Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma.

机构信息

Indiana University School of Medicine, Department of Urology, Indianapolis, Indiana.

Indiana University School of Medicine, Department of Urology, Indianapolis, Indiana.

出版信息

Urol Oncol. 2020 Sep;38(9):739.e1-739.e8. doi: 10.1016/j.urolonc.2020.06.006. Epub 2020 Jul 6.

Abstract

PURPOSE

To investigate oncological outcomes and relapse patterns in retroperitoneal lymph node (LN)-only recurrences with salvage retroperitoneal lymph node dissection (S-RPLND).

MATERIALS AND METHODS

We reviewed records of 19 patients undergoing RPLND for RCC recurrences between 2011 and 2018. All patients initially had primary non-metastatic RCC, with subsequent recurrence restricted to the retroperitoneal lymph nodes (LN). LN recurrence sites after nephrectomy and relapses after S-RPLND were assessed. The primary outcomes were post-RPLND Relapse-Free Survival (RFS), and Cancer-Specific Survival (CSS).

RESULTS

The median age of our cohort was 60 years at RPLND. Right and left nephrectomies were performed in 14 (73.7%) and 5 (26.3%), respectively. Clear cell carcinoma was found in 10 (52.6%) patients, followed by papillary in 4(21.1%), chromophobe in 2(10.5%), and 'other' in 3 (15.8%). The extent of lymphadenectomy during nephrectomy and S-RPLND varied based on surgical approach. The median follow-up time after S-RPLND of the entire cohort was 31.53 months, and the median RFS was 9.63 months. Overall, 4 patients died of cancer, of which 3 (75%) were N1 at time of nephrectomy. The CSS after RPLND at 3 and 5 years was 81.5% and 61.1%, respectively. The RFS after RPLND at 2 and 5 years was 44.4% and 29.6%, respectively.

CONCLUSIONS

Our results suggest that aggressive surgical management provides satisfactory CSS with acceptable complication rates. Moreover, we believe this subset of patients with node-only recurrence showed an unpredictable pattern of lymphatic spread, with predilection for regional dissemination warranting surgical resection of LN recurrences in a bilateral template fashion when feasible.

摘要

目的

探讨挽救性腹膜后淋巴结清扫术(S-RPLND)治疗腹膜后淋巴结(LN)复发的肿瘤学结果和复发模式。

材料与方法

我们回顾了 2011 年至 2018 年间接受 RPLND 治疗肾细胞癌(RCC)复发的 19 例患者的记录。所有患者最初均患有原发性非转移性 RCC,随后复发仅限于腹膜后 LN。评估了肾切除术后的 LN 复发部位和 S-RPLND 后的复发情况。主要结局是 RPLND 后无复发生存期(RFS)和癌症特异性生存期(CSS)。

结果

我们队列的中位年龄为 RPLND 时的 60 岁。14 例(73.7%)行右侧肾切除术,5 例(26.3%)行左侧肾切除术。10 例(52.6%)患者为透明细胞癌,其次是乳头状癌 4 例(21.1%)、嫌色细胞癌 2 例(10.5%)和“其他”3 例(15.8%)。肾切除术和 S-RPLND 期间的淋巴结清扫范围因手术方式而异。整个队列 S-RPLND 后的中位随访时间为 31.53 个月,中位 RFS 为 9.63 个月。总体而言,4 例患者死于癌症,其中 3 例(75%)在肾切除术时为 N1。RPLND 后 3 年和 5 年的 CSS 分别为 81.5%和 61.1%。RPLND 后 2 年和 5 年的 RFS 分别为 44.4%和 29.6%。

结论

我们的结果表明,积极的手术治疗可提供令人满意的 CSS,且并发症发生率可接受。此外,我们认为,这组仅有淋巴结复发的患者表现出不可预测的淋巴扩散模式,区域播散倾向需要在可行的情况下以双侧模板方式切除 LN 复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验